{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:56:24Z","timestamp":1771023384871,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1211,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[1998,9]]},"abstract":"<jats:p>Several complement modulating effects of high\u2010dose intravenous immunoglobulins (IVIG) have been proposed from <jats:italic>in vitro<\/jats:italic> studies and experimental animal models. However, the <jats:italic>in vivo<\/jats:italic> effects of IVIG on plasma complement in humans are yet not known. We have investigated the <jats:italic>in vivo<\/jats:italic> effects of IVIG on complement in seven women with unexplained recurrent spontaneous abortion who were without evidence of autoimmune disease. Samples were obtained before and after the very first infusion of IVIG. There was a marked increase in immunoglobulin G (IgG) from (median and range) 12.4 (9.4\u201315.9) to 26.8 (22.4\u201330.0) g\/l but no change in immunoglobulin A (IgA) or immunoglobulin M (IgM). A significantly increased complement activation was demonstrated using neoepitope\u2010specific enzyme immunoassays to the activation products C3bc (median increased from 9.8 to 31.2 AU\/ml), Bb (0.66\u20131.66 g\/ml), C5a (10.5\u201312.7\u2003ng\/ml), and TCC (0.81\u20132.19 AU\/ml) (<jats:italic>P\u2003<\/jats:italic>=\u20030.015 for all). There were no changes in antigenic concentrations of individual complement components or regulators (C1q, C4, C3, C1\u2010inhibitor, C4b\u2010binding protein) and no decrease in complement haemolytic activity (classical and alternative CH50), which were all within the normal range. The classical pathway activation products C1rs\/C1\u2010inhibitor complexes, C4bc and C4d were elevated in all patients before IVIG treatment and did not change significantly during treatment. In conclusion, IVIG induced a significant activation of complement <jats:italic>in vivo<\/jats:italic>.<\/jats:p>","DOI":"10.1046\/j.1365-3083.1998.00386.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T20:10:38Z","timestamp":1047499838000},"page":"312-317","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["High\u2010Dose Intravenous Immunoglobulin Treatment Activates Complement <i>In Vivo<\/i>"],"prefix":"10.1111","volume":"48","author":[{"family":"Mollnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"H\u00f8g\u00e5sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"De Carolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Perricone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.1996.104.s1.3"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199530950-00010"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1055\/s-0038-1642516","article-title":"High\u2010dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome","volume":"71","author":"Arnout J","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1994.tb01127.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90595-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/pd.1970150603"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1995.tb00960.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00494.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00168.x"},{"key":"e_1_2_6_11_2","first-page":"125","article-title":"Successful high dose intravenous immunoglobulins (IVIG) treatment in recurrent autoimmune or alloimmune spontaneous abortion","volume":"10","author":"De Carolis C","year":"1997","journal-title":"Int J Immunopathol Pharmacol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1994.tb13584.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1994.tb01126.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a135769"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(97)80043-9"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117520"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1995.tb03711.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(94)90303-4"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1995.tb03591.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.1997.d01-168.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1182\/blood.V72.6.1841.1841","article-title":"Quantification of plasma factor XIIa\u2010Cl\u2010inhibitor and kallikrein\u2010Cl\u2010inhibitor complexes in sepsis","volume":"72","author":"Nuijens JH","year":"1988","journal-title":"Blood"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(93)90240-8"},{"key":"e_1_2_6_24_2","unstructured":"MollnesTE. Analysis ofin vivocomplement activation. In: Herzenberg LA Weir DM Herzenberg LA Blackwell C eds. Weir's Handbook of Experimental Immunology 5th edn. Boston: Blackwell Science Ltd 1997;78:18."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(92)90091-7"},{"key":"e_1_2_6_26_2","first-page":"79","article-title":"Side\u2010effects of intravenous immune globulins","volume":"97","author":"Duhem C","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_6_27_2","first-page":"S53","article-title":"Safety and side effects of i.v. immunoglobulin therapy","volume":"14","author":"Nydegger UE","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114387"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(85)90027-3"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(97)00091-6"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V88.1.184.184","article-title":"High doses of immunoglobulin G attenuate immune aggregate\u2010mediated complement activation by enhancing physiologic cleavage of C3b in C3b(n)\u2010IgG complexes","volume":"88","author":"Lutz HU","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(95)80027-1"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(83)90087-1"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-3083.1998.00386.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-3083.1998.00386.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T05:14:27Z","timestamp":1698470067000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-3083.1998.00386.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,9]]}},"alternative-id":["10.1046\/j.1365-3083.1998.00386.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-3083.1998.00386.x","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,9]]},"assertion":[{"value":"2003-10-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}